These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 33117020

  • 21. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M.
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [Abstract] [Full Text] [Related]

  • 22. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 23. Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center.
    De Padua V, Romeo U, Santoro C, Bosco R, Baldacci E, Ferretti A, Malaspina F, Mazzucconi MG, Gaglioti D.
    Heliyon; 2020 Feb; 6(2):e03426. PubMed ID: 32140581
    [Abstract] [Full Text] [Related]

  • 24. In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products.
    Turecek PL, Ilk R, Gritsch H.
    Haemophilia; 2024 Jan; 30(1):151-160. PubMed ID: 37926687
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB.
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W, Krekeler S, Wolf Z, Seifried E.
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [Abstract] [Full Text] [Related]

  • 29. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB.
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin®) in paediatric patients under 6 years of age with severe von Willebrand disease.
    Gouider E, Klukowska A, Maes P, Platokouki H, Pujol S, Henriet C, Bridey F, Goudemand J.
    Blood Transfus; 2023 Jan; 21(1):83-92. PubMed ID: 35543677
    [Abstract] [Full Text] [Related]

  • 35. Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.
    Leebeek FWG, Peyvandi F, Tiede A, Castaman G, Escobar M, Wang M, Zülfikar B, Susen S, Miesbach W, Wang S, Wang Y, Zhang J, Özen G.
    Eur J Haematol; 2023 Jul; 111(1):29-40. PubMed ID: 36823994
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM, Escobar MA.
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.